VALSARTAN
17 general benefit · 7 not a benefit
Other products in the same Health Canada class (C09CA) — coverage varies; not interchangeable
- Candesartan cilexetil (Atacand): general benefit
- Irbesartan (Avapro): general benefit, Not a benefit
- Losartan (Cozaar): general benefit
- Olmesartan medoxomil (Olmetec): general benefit
- Telmisartan (Micardis): general benefit
- Azilsartan medoxomil (Edarbi): not a benefit
1 more in the class list below
Auro-Valsartan · DIN 02414228 · 80mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Valsartan · DIN 02414228
Manufacturer: Auro Pharma Inc.; listing date 2014-05-29
Health Canada: Marketed since 2014-02-06 · brand AURO-VALSARTAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 80 MG · company Auro pharma inc · schedule Prescription
Auro-Valsartan: Formulary list price $0.2159/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2159 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89888 · Verify on the e-Formulary ↗ (DIN 02414228)
Source record
DIN 02414228: Auro-Valsartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800254; group id 357; item number 0829; lccId None; manufacturer id AUR
Source form: Tab; strength: 80mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2159; ministry $0.2159
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02414228
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89888
Interchangeable products
Apo-Valsartan · DIN 02371529 · $0.2159
Co Valsartan · DIN 02337495 · $0.2159
Diovan · DIN 02244781 · $0.2159
M-Valsartan · DIN 02524538 · $0.2159
Sandoz Valsartan · DIN 02356759 · $0.2159
Taro-Valsartan · DIN 02363100 · $0.2159
Teva-Valsartan · DIN 02356651 · $0.2159
Valsartan · DIN 02366959 · $0.2159
Valsartan · DIN 02384531 · $0.2159
Shortage status: resolved shortage (ended 2025-11-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02414228
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Diovan · DIN 02244781 · 80mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diovan · DIN 02244781
Manufacturer: Novartis Pharma Canada Inc.; listing date 2003-09-04
Health Canada: Marketed since 2003-01-24 · brand DIOVAN 80MG TABLETS · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 80 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Ministry pays: $0.2159 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68771 · Verify on the e-Formulary ↗ (DIN 02244781)
Source record
DIN 02244781: Diovan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800254; group id 357; item number 0829; lccId None; manufacturer id NOV
Source form: Tab; strength: 80mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.5580; ministry $0.2159
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244781
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68771
Interchangeable products
Apo-Valsartan · DIN 02371529 · $0.2159
Auro-Valsartan · DIN 02414228 · $0.2159
Co Valsartan · DIN 02337495 · $0.2159
M-Valsartan · DIN 02524538 · $0.2159
Sandoz Valsartan · DIN 02356759 · $0.2159
Taro-Valsartan · DIN 02363100 · $0.2159
Teva-Valsartan · DIN 02356651 · $0.2159
Valsartan · DIN 02366959 · $0.2159
Valsartan · DIN 02384531 · $0.2159
Shortage status: resolved shortage (ended 2020-03-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244781
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Valsartan · DIN 02356759 · 80mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Valsartan · DIN 02356759
Manufacturer: Sandoz Canada Inc.; listing date 2011-06-08
Health Canada: Marketed since 2014-09-16 · brand SANDOZ VALSARTAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 80 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Valsartan: Formulary list price $0.2159/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2159 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84188 · Verify on the e-Formulary ↗ (DIN 02356759)
Source record
DIN 02356759: Sandoz Valsartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800254; group id 357; item number 0829; lccId None; manufacturer id SDZ
Source form: Tab; strength: 80mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2159; ministry $0.2159
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02356759
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84188
Interchangeable products
Apo-Valsartan · DIN 02371529 · $0.2159
Auro-Valsartan · DIN 02414228 · $0.2159
Co Valsartan · DIN 02337495 · $0.2159
Diovan · DIN 02244781 · $0.2159
M-Valsartan · DIN 02524538 · $0.2159
Taro-Valsartan · DIN 02363100 · $0.2159
Teva-Valsartan · DIN 02356651 · $0.2159
Valsartan · DIN 02366959 · $0.2159
Valsartan · DIN 02384531 · $0.2159
Shortage status: resolved shortage (ended 2024-02-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02356759
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Taro-Valsartan · DIN 02363100 · 80mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Taro-Valsartan · DIN 02363100
Manufacturer: Sun Pharma; listing date 2011-06-08
Health Canada: Marketed since 2021-08-18 · brand TARO-VALSARTAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 80 MG · company Sun pharma canada inc · schedule Prescription
Taro-Valsartan: Formulary list price $0.2159/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2159 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84812 · Verify on the e-Formulary ↗ (DIN 02363100)
Source record
DIN 02363100: Taro-Valsartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800254; group id 357; item number 0829; lccId None; manufacturer id SPC
Source form: Tab; strength: 80mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2159; ministry $0.2159
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02363100
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84812
Interchangeable products
Apo-Valsartan · DIN 02371529 · $0.2159
Auro-Valsartan · DIN 02414228 · $0.2159
Co Valsartan · DIN 02337495 · $0.2159
Diovan · DIN 02244781 · $0.2159
M-Valsartan · DIN 02524538 · $0.2159
Sandoz Valsartan · DIN 02356759 · $0.2159
Teva-Valsartan · DIN 02356651 · $0.2159
Valsartan · DIN 02366959 · $0.2159
Valsartan · DIN 02384531 · $0.2159
Shortage status: resolved shortage (ended 2026-03-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02363100
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Valsartan · DIN 02356651 · 80mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Valsartan · DIN 02356651
Manufacturer: Teva Canada Limited; listing date 2011-06-08
Health Canada: Marketed since 2011-02-16 · brand TEVA-VALSARTAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 80 MG · company Teva canada limited · schedule Prescription
Teva-Valsartan: Formulary list price $0.2159/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2159 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84179 · Verify on the e-Formulary ↗ (DIN 02356651)
Source record
DIN 02356651: Teva-Valsartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800254; group id 357; item number 0829; lccId None; manufacturer id TEV
Source form: Tab; strength: 80mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2159; ministry $0.2159
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02356651
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84179
Interchangeable products
Apo-Valsartan · DIN 02371529 · $0.2159
Auro-Valsartan · DIN 02414228 · $0.2159
Co Valsartan · DIN 02337495 · $0.2159
Diovan · DIN 02244781 · $0.2159
M-Valsartan · DIN 02524538 · $0.2159
Sandoz Valsartan · DIN 02356759 · $0.2159
Taro-Valsartan · DIN 02363100 · $0.2159
Valsartan · DIN 02366959 · $0.2159
Valsartan · DIN 02384531 · $0.2159
Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02356651
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Valsartan · DIN 02366959 · 80mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Valsartan · DIN 02366959
Manufacturer: Sanis Health Inc.; listing date 2020-09-30
Health Canada: Marketed since 2021-12-10 · brand VALSARTAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 80 MG · company Sanis health inc · schedule Prescription
Valsartan: Formulary list price $0.2159/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2159 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85177 · Verify on the e-Formulary ↗ (DIN 02366959)
Source record
DIN 02366959: Valsartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800254; group id 357; item number 0829; lccId None; manufacturer id SAI
Source form: Tab; strength: 80mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2159; ministry $0.2159
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02366959
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85177
Interchangeable products
Apo-Valsartan · DIN 02371529 · $0.2159
Auro-Valsartan · DIN 02414228 · $0.2159
Co Valsartan · DIN 02337495 · $0.2159
Diovan · DIN 02244781 · $0.2159
M-Valsartan · DIN 02524538 · $0.2159
Sandoz Valsartan · DIN 02356759 · $0.2159
Taro-Valsartan · DIN 02363100 · $0.2159
Teva-Valsartan · DIN 02356651 · $0.2159
Valsartan · DIN 02384531 · $0.2159
Shortage status: resolved shortage (ended 2020-02-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02366959
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Valsartan · DIN 02384531 · 80mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Valsartan · DIN 02384531
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2021-09-30
Health Canada: Marketed since 2022-05-03 · brand VALSARTAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 80 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Valsartan: Formulary list price $0.2159/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2159 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87025 · Verify on the e-Formulary ↗ (DIN 02384531)
Source record
DIN 02384531: Valsartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800254; group id 357; item number 0829; lccId None; manufacturer id SIV
Source form: Tab; strength: 80mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2159; ministry $0.2159
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02384531
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87025
Interchangeable products
Apo-Valsartan · DIN 02371529 · $0.2159
Auro-Valsartan · DIN 02414228 · $0.2159
Co Valsartan · DIN 02337495 · $0.2159
Diovan · DIN 02244781 · $0.2159
M-Valsartan · DIN 02524538 · $0.2159
Sandoz Valsartan · DIN 02356759 · $0.2159
Taro-Valsartan · DIN 02363100 · $0.2159
Teva-Valsartan · DIN 02356651 · $0.2159
Valsartan · DIN 02366959 · $0.2159
Shortage status: resolved shortage (ended 2021-08-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02384531
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Valsartan · DIN 02414236 · 160mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Valsartan · DIN 02414236
Manufacturer: Auro Pharma Inc.; listing date 2014-05-29
Health Canada: Marketed since 2014-02-06 · brand AURO-VALSARTAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 160 MG · company Auro pharma inc · schedule Prescription
Auro-Valsartan: Formulary list price $0.2159/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2159 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89889 · Verify on the e-Formulary ↗ (DIN 02414236)
Source record
DIN 02414236: Auro-Valsartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800255; group id 357; item number 0830; lccId None; manufacturer id AUR
Source form: Tab; strength: 160mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2159; ministry $0.2159
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02414236
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89889
Interchangeable products
Apo-Valsartan · DIN 02371537 · $0.2159
Co Valsartan · DIN 02337509 · $0.2159
Diovan · DIN 02244782 · $0.2159
M-Valsartan · DIN 02524546 · $0.2159
Sandoz Valsartan · DIN 02356767 · $0.2159
Taro-Valsartan · DIN 02363119 · $0.2159
Teva-Valsartan · DIN 02356678 · $0.2159
Valsartan · DIN 02366967 · $0.2159
Valsartan · DIN 02384558 · $0.2159
Shortage status: resolved shortage (ended 2025-11-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02414236
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Diovan · DIN 02244782 · 160mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diovan · DIN 02244782
Manufacturer: Novartis Pharma Canada Inc.; listing date 2003-09-04
Health Canada: Marketed since 2003-01-24 · brand DIOVAN 160MG TABLETS · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 160 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Ministry pays: $0.2159 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68772 · Verify on the e-Formulary ↗ (DIN 02244782)
Source record
DIN 02244782: Diovan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800255; group id 357; item number 0830; lccId None; manufacturer id NOV
Source form: Tab; strength: 160mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.5529; ministry $0.2159
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244782
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68772
Interchangeable products
Apo-Valsartan · DIN 02371537 · $0.2159
Auro-Valsartan · DIN 02414236 · $0.2159
Co Valsartan · DIN 02337509 · $0.2159
M-Valsartan · DIN 02524546 · $0.2159
Sandoz Valsartan · DIN 02356767 · $0.2159
Taro-Valsartan · DIN 02363119 · $0.2159
Teva-Valsartan · DIN 02356678 · $0.2159
Valsartan · DIN 02366967 · $0.2159
Valsartan · DIN 02384558 · $0.2159
Shortage status: resolved shortage (ended 2020-03-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244782
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Valsartan · DIN 02356767 · 160mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Valsartan · DIN 02356767
Manufacturer: Sandoz Canada Inc.; listing date 2011-06-08
Health Canada: Marketed since 2014-09-16 · brand SANDOZ VALSARTAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 160 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Valsartan: Formulary list price $0.2159/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2159 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84189 · Verify on the e-Formulary ↗ (DIN 02356767)
Source record
DIN 02356767: Sandoz Valsartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800255; group id 357; item number 0830; lccId None; manufacturer id SDZ
Source form: Tab; strength: 160mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2159; ministry $0.2159
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02356767
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84189
Interchangeable products
Apo-Valsartan · DIN 02371537 · $0.2159
Auro-Valsartan · DIN 02414236 · $0.2159
Co Valsartan · DIN 02337509 · $0.2159
Diovan · DIN 02244782 · $0.2159
M-Valsartan · DIN 02524546 · $0.2159
Taro-Valsartan · DIN 02363119 · $0.2159
Teva-Valsartan · DIN 02356678 · $0.2159
Valsartan · DIN 02366967 · $0.2159
Valsartan · DIN 02384558 · $0.2159
Shortage status: resolved shortage (ended 2025-05-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02356767
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Taro-Valsartan · DIN 02363119 · 160mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Taro-Valsartan · DIN 02363119
Manufacturer: Sun Pharma; listing date 2011-06-08
Health Canada: Marketed since 2021-08-18 · brand TARO-VALSARTAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 160 MG · company Sun pharma canada inc · schedule Prescription
Taro-Valsartan: Formulary list price $0.2159/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2159 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84813 · Verify on the e-Formulary ↗ (DIN 02363119)
Source record
DIN 02363119: Taro-Valsartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800255; group id 357; item number 0830; lccId None; manufacturer id SPC
Source form: Tab; strength: 160mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2159; ministry $0.2159
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02363119
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84813
Interchangeable products
Apo-Valsartan · DIN 02371537 · $0.2159
Auro-Valsartan · DIN 02414236 · $0.2159
Co Valsartan · DIN 02337509 · $0.2159
Diovan · DIN 02244782 · $0.2159
M-Valsartan · DIN 02524546 · $0.2159
Sandoz Valsartan · DIN 02356767 · $0.2159
Teva-Valsartan · DIN 02356678 · $0.2159
Valsartan · DIN 02366967 · $0.2159
Valsartan · DIN 02384558 · $0.2159
Shortage status: active shortage (reported 2026-08-12, estimated to end 2026-09-18, last updated 2026-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02363119
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Valsartan · DIN 02356678 · 160mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Valsartan · DIN 02356678
Manufacturer: Teva Canada Limited; listing date 2011-06-08
Health Canada: Marketed since 2011-02-16 · brand TEVA-VALSARTAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 160 MG · company Teva canada limited · schedule Prescription
Teva-Valsartan: Formulary list price $0.2159/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2159 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84180 · Verify on the e-Formulary ↗ (DIN 02356678)
Source record
DIN 02356678: Teva-Valsartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800255; group id 357; item number 0830; lccId None; manufacturer id TEV
Source form: Tab; strength: 160mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2159; ministry $0.2159
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02356678
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84180
Interchangeable products
Apo-Valsartan · DIN 02371537 · $0.2159
Auro-Valsartan · DIN 02414236 · $0.2159
Co Valsartan · DIN 02337509 · $0.2159
Diovan · DIN 02244782 · $0.2159
M-Valsartan · DIN 02524546 · $0.2159
Sandoz Valsartan · DIN 02356767 · $0.2159
Taro-Valsartan · DIN 02363119 · $0.2159
Valsartan · DIN 02366967 · $0.2159
Valsartan · DIN 02384558 · $0.2159
Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02356678
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Valsartan · DIN 02366967 · 160mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Valsartan · DIN 02366967
Manufacturer: Sanis Health Inc.; listing date 2020-09-30
Health Canada: Marketed since 2021-12-10 · brand VALSARTAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 160 MG · company Sanis health inc · schedule Prescription
Valsartan: Formulary list price $0.2159/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2159 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85178 · Verify on the e-Formulary ↗ (DIN 02366967)
Source record
DIN 02366967: Valsartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800255; group id 357; item number 0830; lccId None; manufacturer id SAI
Source form: Tab; strength: 160mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2159; ministry $0.2159
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02366967
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85178
Interchangeable products
Apo-Valsartan · DIN 02371537 · $0.2159
Auro-Valsartan · DIN 02414236 · $0.2159
Co Valsartan · DIN 02337509 · $0.2159
Diovan · DIN 02244782 · $0.2159
M-Valsartan · DIN 02524546 · $0.2159
Sandoz Valsartan · DIN 02356767 · $0.2159
Taro-Valsartan · DIN 02363119 · $0.2159
Teva-Valsartan · DIN 02356678 · $0.2159
Valsartan · DIN 02384558 · $0.2159
Shortage status: resolved shortage (ended 2021-02-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02366967
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Valsartan · DIN 02384558 · 160mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Valsartan · DIN 02384558
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2021-09-30
Health Canada: Marketed since 2022-05-03 · brand VALSARTAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 160 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Valsartan: Formulary list price $0.2159/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2159 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87026 · Verify on the e-Formulary ↗ (DIN 02384558)
Source record
DIN 02384558: Valsartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800255; group id 357; item number 0830; lccId None; manufacturer id SIV
Source form: Tab; strength: 160mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2159; ministry $0.2159
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02384558
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87026
Interchangeable products
Apo-Valsartan · DIN 02371537 · $0.2159
Auro-Valsartan · DIN 02414236 · $0.2159
Co Valsartan · DIN 02337509 · $0.2159
Diovan · DIN 02244782 · $0.2159
M-Valsartan · DIN 02524546 · $0.2159
Sandoz Valsartan · DIN 02356767 · $0.2159
Taro-Valsartan · DIN 02363119 · $0.2159
Teva-Valsartan · DIN 02356678 · $0.2159
Valsartan · DIN 02366967 · $0.2159
Shortage status: resolved shortage (ended 2021-08-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02384558
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Valsartan · DIN 02414244 · 320mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Valsartan · DIN 02414244
Manufacturer: Auro Pharma Inc.; listing date 2014-05-29
Health Canada: Marketed since 2014-02-06 · brand AURO-VALSARTAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 320 MG · company Auro pharma inc · schedule Prescription
Auro-Valsartan: Formulary list price $0.2098/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2098 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89890 · Verify on the e-Formulary ↗ (DIN 02414244)
Source record
DIN 02414244: Auro-Valsartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800272; group id 357; item number 0831; lccId None; manufacturer id AUR
Source form: Tab; strength: 320mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02414244
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89890
Interchangeable products
Apo-Valsartan · DIN 02371545 · $0.2098
Co Valsartan · DIN 02337517 · $0.2098
Diovan · DIN 02289504 · $0.2098
Sandoz Valsartan · DIN 02356775 · $0.2098
Teva-Valsartan · DIN 02356686 · $0.2098
Valsartan · DIN 02366975 · $0.2098
Valsartan · DIN 02384566 · $0.2098
Shortage status: resolved shortage (ended 2025-11-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02414244
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Diovan · DIN 02289504 · 320mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diovan · DIN 02289504
Manufacturer: Novartis Pharma Canada Inc.; listing date 2008-02-12
Health Canada: Marketed since 2007-02-14 · brand DIOVAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 320 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Ministry pays: $0.2098 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77486 · Verify on the e-Formulary ↗ (DIN 02289504)
Source record
DIN 02289504: Diovan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800272; group id 357; item number 0831; lccId None; manufacturer id NOV
Source form: Tab; strength: 320mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.5124; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02289504
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77486
Interchangeable products
Apo-Valsartan · DIN 02371545 · $0.2098
Auro-Valsartan · DIN 02414244 · $0.2098
Co Valsartan · DIN 02337517 · $0.2098
Sandoz Valsartan · DIN 02356775 · $0.2098
Teva-Valsartan · DIN 02356686 · $0.2098
Valsartan · DIN 02366975 · $0.2098
Valsartan · DIN 02384566 · $0.2098
Shortage status: resolved shortage (ended 2020-04-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02289504
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Valsartan · DIN 02356775 · 320mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Valsartan · DIN 02356775
Manufacturer: Sandoz Canada Inc.; listing date 2011-06-08
Health Canada: Marketed since 2014-09-16 · brand SANDOZ VALSARTAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 320 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Valsartan: Formulary list price $0.2098/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2098 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84190 · Verify on the e-Formulary ↗ (DIN 02356775)
Source record
DIN 02356775: Sandoz Valsartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800272; group id 357; item number 0831; lccId None; manufacturer id SDZ
Source form: Tab; strength: 320mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2098; ministry $0.2098
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02356775
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84190
Interchangeable products
Apo-Valsartan · DIN 02371545 · $0.2098
Auro-Valsartan · DIN 02414244 · $0.2098
Co Valsartan · DIN 02337517 · $0.2098
Diovan · DIN 02289504 · $0.2098
Teva-Valsartan · DIN 02356686 · $0.2098
Valsartan · DIN 02366975 · $0.2098
Valsartan · DIN 02384566 · $0.2098
Shortage status: resolved shortage (ended 2024-09-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02356775
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Valsartan · DIN 02414201 · 40mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Valsartan · DIN 02414201
Manufacturer: Auro Pharma Inc.; listing date 2014-08-28
Health Canada: Marketed since 2014-02-06 · brand AURO-VALSARTAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 40 MG · company Auro pharma inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89887 · Verify on the e-Formulary ↗ (DIN 02414201)
Source record
DIN 02414201: Auro-Valsartan
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240800295; group id 357; item number 0828; lccId None; manufacturer id AUR
Source form: Tab; strength: 40mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.5823; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02414201
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89887
Interchangeable products
Apo-Valsartan · DIN 02371510 · not recorded
Co Valsartan · DIN 02337487 · not recorded
Diovan · DIN 02270528 · not recorded
M-Valsartan · DIN 02524511 · not recorded
Sandoz Valsartan · DIN 02356740 · not recorded
Taro-Valsartan · DIN 02363062 · not recorded
Teva-Valsartan · DIN 02356643 · not recorded
Valsartan · DIN 02366940 · not recorded
Valsartan · DIN 02384523 · not recorded
Shortage status: resolved shortage (ended 2025-09-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02414201
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Diovan · DIN 02270528 · 40mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diovan · DIN 02270528
Manufacturer: Novartis Pharma Canada Inc.; listing date 2011-06-08
Health Canada: Marketed since 2005-11-01 · brand DIOVAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 40 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Diovan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75588 · Verify on the e-Formulary ↗ (DIN 02270528)
Source record
DIN 02270528: Diovan
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240800295; group id 357; item number 0828; lccId None; manufacturer id NOV
Source form: Tab; strength: 40mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02270528
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75588
Interchangeable products
Apo-Valsartan · DIN 02371510 · not recorded
Auro-Valsartan · DIN 02414201 · not recorded
Co Valsartan · DIN 02337487 · not recorded
M-Valsartan · DIN 02524511 · not recorded
Sandoz Valsartan · DIN 02356740 · not recorded
Taro-Valsartan · DIN 02363062 · not recorded
Teva-Valsartan · DIN 02356643 · not recorded
Valsartan · DIN 02366940 · not recorded
Valsartan · DIN 02384523 · not recorded
Shortage status: resolved shortage (ended 2020-05-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02270528
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Valsartan · DIN 02356740 · 40mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Valsartan · DIN 02356740
Manufacturer: Sandoz Canada Inc.; listing date 2011-08-04
Health Canada: Marketed since 2014-09-16 · brand SANDOZ VALSARTAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 40 MG · company Sandoz canada incorporated · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84187 · Verify on the e-Formulary ↗ (DIN 02356740)
Source record
DIN 02356740: Sandoz Valsartan
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240800295; group id 357; item number 0828; lccId None; manufacturer id SDZ
Source form: Tab; strength: 40mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.5823; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02356740
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84187
Interchangeable products
Apo-Valsartan · DIN 02371510 · not recorded
Auro-Valsartan · DIN 02414201 · not recorded
Co Valsartan · DIN 02337487 · not recorded
Diovan · DIN 02270528 · not recorded
M-Valsartan · DIN 02524511 · not recorded
Taro-Valsartan · DIN 02363062 · not recorded
Teva-Valsartan · DIN 02356643 · not recorded
Valsartan · DIN 02366940 · not recorded
Valsartan · DIN 02384523 · not recorded
Shortage status: resolved shortage (ended 2020-08-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02356740
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Taro-Valsartan · DIN 02363062 · 40mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Taro-Valsartan · DIN 02363062
Manufacturer: Sun Pharma; listing date 2011-06-08
Health Canada: Marketed since 2021-08-18 · brand TARO-VALSARTAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 40 MG · company Sun pharma canada inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84808 · Verify on the e-Formulary ↗ (DIN 02363062)
Source record
DIN 02363062: Taro-Valsartan
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240800295; group id 357; item number 0828; lccId None; manufacturer id SPC
Source form: Tab; strength: 40mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.5823; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02363062
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84808
Interchangeable products
Apo-Valsartan · DIN 02371510 · not recorded
Auro-Valsartan · DIN 02414201 · not recorded
Co Valsartan · DIN 02337487 · not recorded
Diovan · DIN 02270528 · not recorded
M-Valsartan · DIN 02524511 · not recorded
Sandoz Valsartan · DIN 02356740 · not recorded
Teva-Valsartan · DIN 02356643 · not recorded
Valsartan · DIN 02366940 · not recorded
Valsartan · DIN 02384523 · not recorded
Shortage status: resolved shortage (ended 2026-09-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02363062
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Valsartan · DIN 02356643 · 40mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Valsartan · DIN 02356643
Manufacturer: Teva Canada Limited; listing date 2011-06-08
Health Canada: Marketed since 2011-02-16 · brand TEVA-VALSARTAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 40 MG · company Teva canada limited · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84178 · Verify on the e-Formulary ↗ (DIN 02356643)
Source record
DIN 02356643: Teva-Valsartan
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240800295; group id 357; item number 0828; lccId None; manufacturer id TEV
Source form: Tab; strength: 40mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.5823; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02356643
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84178
Interchangeable products
Apo-Valsartan · DIN 02371510 · not recorded
Auro-Valsartan · DIN 02414201 · not recorded
Co Valsartan · DIN 02337487 · not recorded
Diovan · DIN 02270528 · not recorded
M-Valsartan · DIN 02524511 · not recorded
Sandoz Valsartan · DIN 02356740 · not recorded
Taro-Valsartan · DIN 02363062 · not recorded
Valsartan · DIN 02366940 · not recorded
Valsartan · DIN 02384523 · not recorded
Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02356643
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Valsartan · DIN 02366940 · 40mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Valsartan · DIN 02366940
Manufacturer: Sanis Health Inc.; listing date 2020-10-30
Health Canada: Marketed since 2021-12-10 · brand VALSARTAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 40 MG · company Sanis health inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85176 · Verify on the e-Formulary ↗ (DIN 02366940)
Source record
DIN 02366940: Valsartan
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240800295; group id 357; item number 0828; lccId None; manufacturer id SAI
Source form: Tab; strength: 40mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.5823; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02366940
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85176
Interchangeable products
Apo-Valsartan · DIN 02371510 · not recorded
Auro-Valsartan · DIN 02414201 · not recorded
Co Valsartan · DIN 02337487 · not recorded
Diovan · DIN 02270528 · not recorded
M-Valsartan · DIN 02524511 · not recorded
Sandoz Valsartan · DIN 02356740 · not recorded
Taro-Valsartan · DIN 02363062 · not recorded
Teva-Valsartan · DIN 02356643 · not recorded
Valsartan · DIN 02384523 · not recorded
Shortage status: resolved shortage (ended 2020-07-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02366940
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Valsartan · DIN 02384523 · 40mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Valsartan · DIN 02384523
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2021-09-30
Health Canada: Marketed since 2022-05-03 · brand VALSARTAN · ATC C09CA03 VALSARTAN · form Tablet · route Oral · ingredients VALSARTAN 40 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87024 · Verify on the e-Formulary ↗ (DIN 02384523)
Source record
DIN 02384523: Valsartan
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 240800295; group id 357; item number 0828; lccId None; manufacturer id SIV
Source form: Tab; strength: 40mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.5823; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02384523
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87024
Interchangeable products
Apo-Valsartan · DIN 02371510 · not recorded
Auro-Valsartan · DIN 02414201 · not recorded
Co Valsartan · DIN 02337487 · not recorded
Diovan · DIN 02270528 · not recorded
M-Valsartan · DIN 02524511 · not recorded
Sandoz Valsartan · DIN 02356740 · not recorded
Taro-Valsartan · DIN 02363062 · not recorded
Teva-Valsartan · DIN 02356643 · not recorded
Valsartan · DIN 02366940 · not recorded
Shortage status: discontinued (2021-08-16, reported by SIVEM PHARMACEUTICALS ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02384523
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered
Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE
Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VERAPAMIL HCL
24:08 Hypotensive Drugs (For Diuretics See 40:28)
· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab
· 41 products · Listed, not a benefit (1), General benefit (40) · strengths: 75mg, 150mg, 300mg · Tab
· 42 products · General benefit · strengths: 25mg, 50mg, 100mg · Tab
· 22 products · General benefit · strengths: 20mg, 40mg · Tab
· 25 products · General benefit · strengths: 40mg, 80mg · Tab
· 2 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada · strengths: 400mg, 600mg · Tab
· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab
· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab
· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab
· 14 products ·
Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab
· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab
· 2 products · General benefit · strengths: 5mg/12.5mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08
and 34 more
Other drugs in the same formulary class (24:32:08 Angiotensin II Receptor Antagonists) and how they are covered
Matched class: 24:32:08 Angiotensin II Receptor Antagonists
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
No displayed product is listed as a general benefit in this extract. Check its listing requirements below.
24:32:08 Angiotensin II Receptor Antagonists
· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 40mg, 80mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:32:08